Industry news

AstraZeneca rejects latest Pfizer offer

Read time: 1 mins

Last updated:13th May 2014

Published:13th May 2014

Source: Pharmawand

The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc.. Pfizer’s announcement contains no new proposal nor substantive new information. The Board of AstraZeneca believes Pfizer is making an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline. This value should accrue fully to AstraZeneca shareholders. The Board reiterates its confidence in AstraZeneca’s ability to deliver on its prospects as an independent, science led business.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Eyenovia Inc.,to accelerate development of MicroPine and explore alternatives to maximize shareholder value.

Eyenovia, Inc. announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value

1 mins

Industry news

GenMab A/S to acquire ProfoundBio and with it Rina-S, an FRalpha ADC, to treat ovarian cancer

Genmab A/S and ProfoundBio, Inc. announce that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction.

1 min

Industry news

Acorda Therapeutics files for voluntary bankruptcy

Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to Inbrija, Ampyra, and Fampyra for $185 million.

1 min

See all news